These organoids provide scientists with better models for studying liver biology, and for developing treatments for various liver disorders.

CRCs are the third most common cancer and the second leading cause of cancer deaths in the world. However, SRCC is an ...

Importantly, in vivo results in a CLBL-1 xenograft ... human hairy cell leukemia (14, 38). Despite the promising potential of immunotoxins, of the three approved immunotoxins, Moxetumomab pasudotox ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

The poster presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung ...

NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and ...

Title: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases ...

The in vivo anti-lymphoma efficacy and pharmacodynamic effect were evaluated in Raji xenograft model. The tissue resident B cell depletion was assessed in CD34+ hematopoietic stem cells humanized ...

Antengene Corporation Limited ( "Antengene" , SEHK: 6996) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and ...

Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...